How to use the speech recognition tool?

NCT03326336

PIONEER

Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects
With Retinitis Pigmentosa (PIONEER).

Type: Interventional



Status of the trial: Recruiting

Orphan Drug Recognition: No

Inclusion

  • Opening Date: 2018-01-23
  • Closing Date: 2024-05-01

Criteria

More information

Children: No

Adults: Yes

Funder Type: industry

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: